Last year, Rockwell Medical Inc generated 68.93M USD for its biggest-performing segment, Concentrate Products. The United States made the largest contribution, accounting for 60.36M USD last year. For the latest quarter, Rockwell Medical Inc reported the revenue of 17.78M USD for the period ending 2026-06-30, which came from the top-performing segment, Concentrate Products. United States contributed the highest revenue, at 15.13M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Concentrate Products

Drug Products

Concentrate Products –Product Sales – Point-in-time Over time

Concentrate Products –License Fee – Point-in-time

Drug Revenues-License Fee – Over time

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Concentrate Products

68.93M(99.53%)

101.44M(99.95%)

81.27M(97.20%)

71.65M(98.41%)

60.85M(98.26%)

61.06M(98.17%)

--(--)

Drug Products

325.00K(0.47%)

46.00K(0.05%)

2.34M(2.80%)

1.16M(1.59%)

1.08M(1.74%)

1.14M(1.83%)

--(--)

Concentrate Products –Product Sales – Point-in-time Over time

--(--)

58.78M(96.31%)

60.99M(96.22%)

Concentrate Products –License Fee – Point-in-time

--(--)

1.98M(3.24%)

2.12M(3.35%)

Drug Revenues-License Fee – Over time

--(--)

273.00K(0.45%)

273.00K(0.43%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

Rest of World

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

60.36M(87.15%)

92.26M(90.90%)

74.34M(88.91%)

65.77M(90.32%)

55.39M(89.44%)

56.58M(90.97%)

54.52M(89.33%)

54.38M(85.80%)

Rest of World

8.90M(12.85%)

9.23M(9.10%)

9.27M(11.09%)

7.04M(9.68%)

6.54M(10.56%)

5.62M(9.03%)

6.51M(10.67%)

9.00M(14.20%)